Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study

J Dermatol. 2010 Aug;37(8):708-13. doi: 10.1111/j.1346-8138.2010.00882.x.


Although the mechanisms underlying the loss of response to infliximab are not completely understood, the formation of antibodies to infliximab (ATI) are thought to play a role. The aim of this study was to investigate the presence of ATI in psoriatic patients and to evaluate its relationship to the clinical response. Fifteen patients with psoriasis were treated with infliximab (5 mg/kg) every 8 weeks after an initial three-dose induction treatment. An enzyme linked immunosorbent assay kit was used for analyzing the presence of ATI in sera. Effectiveness assessments included the change in Psoriasis Area and Severity Index (PASI) compared with study entry. Five (33.3%) patients developed ATI. While 5.9 +/- 3.2 infliximab infusions achieved a fall in the PASI score from a mean of 20.4 +/- 8.3 to 5.3 +/- 2.4 in ATI-negative patients, these values changed from 23.3 +/- 11 to 10 +/- 4.9 after 9 +/- 5.2 infusions in ATI-positive patients. Our results suggested that ATI measured in psoriatic patients are of clinical importance. Therefore, monitoring for the induction of ATI and rescue strategies should be developed to avoid or to maintain a delay in ATI development.

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Aged
  • Antibodies / blood
  • Antibodies / immunology*
  • Antibodies, Monoclonal / immunology*
  • Antibodies, Monoclonal / therapeutic use
  • Dermatologic Agents / immunology*
  • Dermatologic Agents / therapeutic use
  • Female
  • Humans
  • Infliximab
  • Male
  • Middle Aged
  • Pilot Projects
  • Psoriasis / immunology
  • Psoriasis / therapy*
  • Severity of Illness Index
  • Treatment Outcome


  • Adrenal Cortex Hormones
  • Antibodies
  • Antibodies, Monoclonal
  • Dermatologic Agents
  • Infliximab